Repligen | RGEN - Current Liabilities


Repligen reported $131.14M in Current Liabilities for its fiscal quarter ending in September of 2025.





Current Liabilities Change Date
Agilent USD 2.35B 455M Sep/2025
Align Technology USD 1.97B 29.02M Sep/2025
Bio Techne USD 144.54M 31.3M Sep/2025
BioMarin Pharmaceutical USD 798.44M 114.19M Sep/2025
Bristol-Myers Squibb USD 28.14B 608M Sep/2025
Bruker USD 1.27B 79.3M Sep/2025
Charles River Laboratories USD 1.12B 41.45M Sep/2025
Danaher USD 6.81B 483M Dec/2025
Dentsply International USD 1.4B 239M Sep/2025
Exact Sciences USD 584.26M 62.33M Sep/2025
General Electric Aerospace USD 38.98B 1.78B Dec/2025
Henry Schein USD 3.15B 142M Sep/2025
Illumina USD 1.96B 501M Sep/2025
IQVIA Holdings USD 8.51B 936M Sep/2025
Mettler Toledo International USD 1.19B 85.24M Sep/2025
Myriad Genetics USD 148M 51.9M Sep/2025
Pfizer USD 36.6B 1.13B Sep/2025
Repligen USD 131.14M 8.12M Sep/2025
Revvity USD 1.22B 550.93M Sep/2025
Standard Biotools USD 107.96M 9.94M Sep/2025
Thermo Fisher Scientific USD 15.19B 301M Dec/2025
Waters USD 1.25B 235.17M Sep/2025
West Pharmaceutical Services USD 635.4M 30.8M Sep/2025